Medicxi Ventures Management (jersey) Ltd is an investment fund managing more than $335 billion ran by Giles Johnstone-scott. There are currently 4 companies in Mr. Johnstone-scott’s portfolio. The largest investments include Centessa Pharmaceuticals Plc and Phathom Pharmaceuticals Inc, together worth $257 billion.
As of 9th July 2024, Medicxi Ventures Management (jersey) Ltd’s top holding is 19,963,157 shares of Centessa Pharmaceuticals Plc currently worth over $180 billion and making up 53.8% of the portfolio value.
In addition, the fund holds 7,464,572 shares of Phathom Pharmaceuticals Inc worth $76.9 billion, whose value grew 68.7% in the past six months.
The third-largest holding is Newamsterdam Pharma Company worth $55.1 billion and the next is Aura Biosciences Inc worth $23 billion, with 3,039,892 shares owned.
Currently, Medicxi Ventures Management (jersey) Ltd's portfolio is worth at least $335 billion. The total portfolio value may be much higher due to cash
assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.
The Medicxi Ventures Management (jersey) Ltd office and employees reside in St. Helier, Jersey. According to the last 13-F report filed with the SEC, Giles Johnstone-scott serves as the Director at Medicxi Ventures Management (jersey) Ltd.
There are companies that Medicxi Ventures Management (jersey) Ltd is getting rid of from its portfolio.
Medicxi Ventures Management (jersey) Ltd closed its position in Merus N.V on 16th July 2024.
It sold the previously owned 1,169,028 shares for $52.6 billion.
The two most similar investment funds to Medicxi Ventures Management (jersey) Ltd are Smith & Howard Wealth Management and Alliance Wealth Advisors, ut. They manage $335 billion and $335 billion respectively.
Medicxi Ventures Management (jersey) Ltd’s portfolio is diversified across 2 sectors.
Currently, their heaviest sector is Health Care — making up 22.9% of
the total portfolio value.
The fund focuses on investments in the United States as
25.0% of the portfolio companies
are based in the United States.
The majority of the companies in the fund’s portfolio are large-cap stocks.
Stocks with a size of more than $10 billion in market cap make up
approximately 0.1% of the total holdings value.
On the other hand, small-cap stocks make up only approximately 0.1% of the portfolio.
The average market cap of the portfolio companies is close to $338 million.
These positions were updated on July 16th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.
| Security | Shares Owned | Value | Allocation |
|---|---|---|---|
| Centessa Pharmaceuticals Plc |
No change
19,963,157
|
$180,267,308,000 | 53.77% |
| Phathom Pharmaceuticals Inc |
No change
7,464,572
|
$76,885,092,000 | 22.93% |
| Newamsterdam Pharma Company |
No change
2,869,565
|
$55,124,344,000 | 16.44% |
| Merus N.V |
Closed
1,169,028
|
$52,641,331,000 | |
| Aura Biosciences Inc |
No change
3,039,892
|
$22,981,584,000 | 6.85% |
| No transactions found | |||
| Showing first 500 out of 5 holdings | |||